BeOne Medicines Ltd. - Sponsored ADR (NASDAQ:ONC - Get Free Report) SVP Chan Henry Lee sold 422 shares of the stock in a transaction on Monday, June 16th. The stock was sold at an average price of $266.50, for a total value of $112,463.00. The transaction was disclosed in a document filed with the SEC, which is available at this link.
Chan Henry Lee also recently made the following trade(s):
- On Friday, June 6th, Chan Henry Lee sold 700 shares of BeOne Medicines stock. The stock was sold at an average price of $256.11, for a total value of $179,277.00.
BeOne Medicines Price Performance
Shares of BeOne Medicines stock traded down $5.70 during trading on Friday, hitting $247.08. 230,772 shares of the company were exchanged, compared to its average volume of 298,435. The company has a market capitalization of $27.07 billion, a price-to-earnings ratio of -66.42 and a beta of 0.30. BeOne Medicines Ltd. - Sponsored ADR has a 1-year low of $141.31 and a 1-year high of $287.88. The stock has a fifty day moving average price of $245.59. The company has a debt-to-equity ratio of 0.05, a current ratio of 1.96 and a quick ratio of 1.71.
BeOne Medicines (NASDAQ:ONC - Get Free Report) last released its quarterly earnings data on Wednesday, May 7th. The company reported $1.22 earnings per share for the quarter, beating the consensus estimate of ($0.71) by $1.93. BeOne Medicines had a negative return on equity of 7.55% and a negative net margin of 9.40%. The business had revenue of $1.12 billion for the quarter, compared to analysts' expectations of $1.12 billion. As a group, equities research analysts anticipate that BeOne Medicines Ltd. - Sponsored ADR will post -5.82 earnings per share for the current year.
Analyst Upgrades and Downgrades
A number of analysts recently commented on ONC shares. Bank of America upgraded BeOne Medicines from a "neutral" rating to a "buy" rating and lifted their price objective for the stock from $207.00 to $320.00 in a research report on Monday, March 3rd. Sanford C. Bernstein set a $259.00 price objective on BeOne Medicines in a research report on Thursday, March 13th. Wall Street Zen upgraded BeOne Medicines from a "hold" rating to a "buy" rating in a research report on Thursday, May 22nd. JPMorgan Chase & Co. lifted their price objective on BeOne Medicines from $311.00 to $317.00 and gave the stock an "overweight" rating in a research report on Monday, April 21st. Finally, TD Securities reiterated a "buy" rating and issued a $334.00 price objective on shares of BeOne Medicines in a research report on Thursday, April 24th. Seven analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, BeOne Medicines has a consensus rating of "Buy" and a consensus price target of $319.00.
Check Out Our Latest Stock Report on ONC
About BeOne Medicines
(
Get Free Report)
BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations.
Recommended Stories
Before you consider BeOne Medicines, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and BeOne Medicines wasn't on the list.
While BeOne Medicines currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
